F. Maignen

Comparing access to orphan medicinal products in Europe

Bernarda Zamora, F. Maignen, P. O’Neill et al. · Orphanet Journal of Rare Diseases · 2019 · 87 citations · Full text

Pharmacy, Health Policy, Pharmaceutical Policy +17

Validation of Statistical Signal Detection Procedures in EudraVigilance Post-Authorization Data

Yolanda Álvarez, Ana Andreina Tacuri Hidalgo, F. Maignen et al. · Drug Safety · 2010 · 84 citations

Pharmacy, Biostatistics, Time Series Analysis +6

Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases

F. Maignen, Manfred Hauben, Eric Hung et al. · Pharmacoepidemiology and Drug Safety · 2013 · 49 citations

Pharmacy, Pharmacology, Drug Information +16

A conceptual approach to the masking effect of measures of disproportionality

F. Maignen, Manfred Hauben, Eric Hung et al. · Pharmacoepidemiology and Drug Safety · 2013 · 29 citations

Pharmacy, Biostatistics, Data Analytics +8

How should we assess the clinical and cost effectiveness of histology independent cancer drugs?

Sophie Cooper, Jacoline C. Bouvy, Lawrence Baker et al. · BMJ · 2020 · 21 citations

Pharmacy, Oncology, Pharmacoeconomics +17